Last reviewed · How we verify
Relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after at least two prior lines of therapy for whom MAb-based therapy has failed
Approved treatments
- Itovebi · Pfizer
Inavolisib is a PI3K inhibitor with degradative activity against PI3Kα.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after at least two prior lines of therapy for whom MAb-based therapy has failed patent landscape — cliff calendar, originator estates, attackable patents
- Relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after at least two prior lines of therapy for whom MAb-based therapy has failed treatment landscape brief
- Relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after at least two prior lines of therapy for whom MAb-based therapy has failed treatment updates RSS
Frequently asked questions about Relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after at least two prior lines of therapy for whom MAb-based therapy has failed
What drugs treat Relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after at least two prior lines of therapy for whom MAb-based therapy has failed?
Tracked treatments include Itovebi.
What is the treatment for Relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after at least two prior lines of therapy for whom MAb-based therapy has failed?
Standard treatment for Relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after at least two prior lines of therapy for whom MAb-based therapy has failed includes Itovebi. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after at least two prior lines of therapy for whom MAb-based therapy has failed patent cliff · Relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after at least two prior lines of therapy for whom MAb-based therapy has failed CI report
- Treatment: Itovebi · Pfizer
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing